US2014120129A1PendingUtilityA1
Chlamydia antigens
Est. expiryDec 3, 2027(~1.4 yrs left)· nominal 20-yr term from priority
A61P 31/04C07K 14/295A61K 2039/53A61K 2039/505A61P 37/04A61K 39/00
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia , in a subject.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated CT491 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 1, or fragment thereof, wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
2 . The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment, when administered to a mammal, elicits an immune response.
3 . The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment elicits a CD8 + T-cell response.
4 . The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
5 . The fragment of claim 1 , wherein said fragment is fewer than 400 amino acids in length.
6 . The fragment of claim 5 , wherein said fragment is fewer than 300 amino acids in length.
7 . The fragment of claim 6 , wherein said fragment is fewer than 200 amino acids in length.
8 . The fragment of claim 7 , wherein said fragment is fewer than 100 amino acids in length.
9 . The fragment of claim 8 , wherein said fragment is fewer than 50 amino acids in length.
10 . The fragment of claim 9 , wherein said fragment is fewer than 30 amino acids in length.
11 . The fragment of claim 10 , wherein said fragment is fewer than 15 amino acids in length.
12 . The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 1.
13 . The polypeptide or fragment of claim 12 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
14 . The polypeptide or fragment of claim 12 , wherein said polypeptide or fragment contains at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 1.
15 . The polypeptide or fragment of claim 14 , wherein said polypeptide or fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 1.
16 . A pharmaceutical composition comprising the polypeptide or fragment of claim 1 in a pharmaceutically acceptable carrier.
17 . A vaccine comprising:
a) the polypeptide or fragment of claim 1 , and b) a pharmaceutically acceptable carrier.
18 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide or fragment of claim 1 .
19 . The method of claim 18 , wherein said polypeptide or fragment is in a pharmaceutically acceptable carrier.
20 . The method of claim 18 , wherein said polypeptide or fragment is capable of generating an immune response in said subject.
21 . The method of claim 18 , wherein said bacterial infection is Chlamydia infection.
22 . The method of claim 21 , wherein said subject has or is at risk for contracting Chlamydia.
23 . An isolated fusion protein comprising:
a) the polypeptide or fragment of claim 1 ; and b) a fusion partner.
24 . The fusion protein of claim 23 , wherein said fragment comprises at least one flanking amino acid.
25 . A pharmaceutical composition comprising the fusion protein of claim 23 and a pharmaceutically acceptable carrier.
26 . A vaccine comprising:
a) the fusion protein of claim 23 , and b) a pharmaceutically acceptable carrier.
27 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide or fragment of claim 1 .
28 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 23 .
29 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 27 or 28 .
30 . The method of claim 29 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
31 . The method of claim 29 , wherein said DNA vaccine is capable of generating an immune response in said subject.
32 . The method of claim 29 , wherein said bacterial infection is Chlamydia infection.
33 . The method of claim 32 , wherein said subject has or is at risk for contracting Chlamydia.
34 . An isolated CT601 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 2, or fragment thereof, wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
35 . The polypeptide or fragment of claim 34 , wherein said polypeptide or fragment, when administered to a mammal, elicits an immune response.
36 . The polypeptide or fragment of claim 34 , wherein said polypeptide or fragment elicits a CD8 + T-cell response.
37 . The polypeptide or fragment of claim 34 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
38 . The fragment of claim 34 , wherein said fragment is fewer than 150 amino acids in length.
39 . The fragment of claim 38 , wherein said fragment is fewer than 100 amino acids in length.
40 . The fragment of claim 39 , wherein said fragment is fewer than 50 amino acids in length.
41 . The fragment of claim 40 , wherein said fragment is fewer than 30 amino acids in length.
42 . The fragment of claim 41 , wherein said fragment is fewer than 15 amino acids in length.
43 . The polypeptide or fragment of claim 34 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 2.
44 . The polypeptide or fragment of claim 43 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
45 . The polypeptide or fragment of claim 43 , wherein said polypeptide or fragment at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 2.
46 . The polypeptide or fragment of claim 45 , wherein said polypeptide or fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 2.
47 . A pharmaceutical composition comprising the polypeptide or fragment of claim 34 in a pharmaceutically acceptable carrier.
48 . A vaccine comprising:
a) the polypeptide or fragment of claim 34 , and b) a pharmaceutically acceptable carrier.
49 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide or fragment of claim 34 .
50 . The method of claim 49 , wherein said polypeptide or fragment is in a pharmaceutically acceptable carrier.
51 . The method of claim 49 , wherein said polypeptide or fragment is capable of generating an immune response in said subject.
52 . The method of claim 49 , wherein said bacterial infection is Chlamydia infection.
53 . The method of claim 52 , wherein said subject has or is at risk for contracting Chlamydia.
54 . An isolated fusion protein comprising:
a) the polypeptide or fragment of claim 34 ; and b) a fusion partner.
55 . The fusion protein of claim 54 , wherein said fragment comprises at least one flanking amino acid.
56 . A pharmaceutical composition comprising the fusion protein of claim 54 and a pharmaceutically acceptable carrier.
57 . A vaccine comprising:
a) the fusion protein of claim 54 , and b) a pharmaceutically acceptable carrier.
58 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide or fragment of claim 34 .
59 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 54 .
60 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 58 or 59 .
61 . The method of claim 60 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
62 . The method of claim 60 , wherein said DNA vaccine is capable of generating an immune response in said subject.
63 . The method of claim 60 , wherein said bacterial infection is Chlamydia infection.
64 . The method of claim 63 , wherein said subject has or is at risk for contracting Chlamydia.
65 . An isolated CT687 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 3, or fragment thereof, wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
66 . The polypeptide or fragment of claim 65 , wherein said polypeptide or fragment, when administered to a mammal, elicits an immune response.
67 . The polypeptide or fragment of claim 65 , wherein said polypeptide or fragment elicits a CD8 + T-cell response.
68 . The polypeptide or fragment of claim 65 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
69 . The fragment of claim 65 , wherein said fragment is fewer than 400 amino acids in length.
70 . The fragment of claim 69 , wherein said fragment is fewer than 300 amino acids in length.
71 . The fragment of claim 70 , wherein said fragment is fewer than 200 amino acids in length.
72 . The fragment of claim 71 , wherein said fragment is fewer than 100 amino acids in length.
73 . The fragment of claim 72 , wherein said fragment is fewer than 50 amino acids in length.
74 . The fragment of claim 73 , wherein said fragment is fewer than 30 amino acids in length.
75 . The fragment of claim 74 , wherein said fragment is fewer than 15 amino acids in length.
76 . The polypeptide or fragment of claim 65 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 3.
77 . The polypeptide or fragment of claim 76 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
78 . The polypeptide or fragment of claim 76 , wherein said polypeptide or fragment at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 3.
79 . The polypeptide or fragment of claim 78 , wherein said polypeptide or fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 3.
80 . A pharmaceutical composition comprising the polypeptide or fragment of claim 65 in a pharmaceutically acceptable carrier.
81 . A vaccine comprising:
a) the polypeptide or fragment of claim 65 , and b) a pharmaceutically acceptable carrier.
82 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide or fragment of claim 65 .
83 . The method of claim 82 , wherein said polypeptide or fragment is in a pharmaceutically acceptable carrier.
84 . The method of claim 82 , wherein said polypeptide or fragment is capable of generating an immune response in said subject.
85 . The method of claim 82 , wherein said bacterial infection is Chlamydia infection.
86 . The method of claim 85 , wherein said subject has or is at risk for contracting Chlamydia.
87 . An isolated fusion protein comprising:
a) the polypeptide or fragment of claim 65 ; and b) a fusion partner.
88 . The fusion protein of claim 87 , wherein said fragment comprises at least one flanking amino acid.
89 . A pharmaceutical composition comprising the fusion protein of claim 87 and a pharmaceutically acceptable carrier.
90 . A vaccine comprising:
a) the fusion protein of claim 87 , and b) a pharmaceutically acceptable carrier.
91 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide or fragment of claim 65 .
92 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 87 .
93 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 91 or 92 .
94 . The method of claim 93 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
95 . The method of claim 93 , wherein said DNA vaccine is capable of generating an immune response in said subject.
96 . The method of claim 93 , wherein said bacterial infection is Chlamydia infection.
97 . The method of claim 96 , wherein said subject has or is at risk for contracting Chlamydia.
98 . An isolated CT732 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 4, or fragment thereof, wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
99 . The polypeptide or fragment of claim 98 , wherein said polypeptide or fragment, when administered to a mammal, elicits an immune response.
100 . The polypeptide or fragment of claim 98 , wherein said polypeptide or fragment elicits a CD8 + T-cell response.
101 . The polypeptide or fragment of claim 98 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
102 . The fragment of claim 98 , wherein said fragment is fewer than 150 amino acids in length.
103 . The fragment of claim 102 , wherein said fragment is fewer than 100 amino acids in length.
104 . The fragment of claim 103 , wherein said fragment is fewer than 50 amino acids in length.
105 . The fragment of claim 104 , wherein said fragment is fewer than 30 amino acids in length.
106 . The fragment of claim 105 , wherein said fragment is fewer than 15 amino acids in length.
107 . The polypeptide or fragment of claim 98 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 4.
108 . The polypeptide or fragment of claim 107 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
109 . The polypeptide or fragment of claim 107 , wherein said polypeptide or fragment contains at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 4.
110 . The polypeptide or fragment of claim 109 , wherein said polypeptide or fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 4.
111 . A pharmaceutical composition comprising the polypeptide or fragment of claim 98 in a pharmaceutically acceptable carrier.
112 . A vaccine comprising:
a) the polypeptide or fragment of claim 98 , and b) a pharmaceutically acceptable carrier.
113 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide or fragment of claim 98 .
114 . The method of claim 113 , wherein said polypeptide or fragment is in a pharmaceutically acceptable carrier.
115 . The method of claim 113 , wherein said polypeptide or fragment is capable of generating an immune response in said subject.
116 . The method of claim 113 , wherein said bacterial infection is Chlamydia infection.
117 . The method of claim 116 , wherein said subject has or is at risk for contracting Chlamydia.
118 . An isolated fusion protein comprising:
a) the polypeptide or fragment of claim 98 ; and b) a fusion partner.
119 . The fusion protein of claim 118 , wherein said fragment comprises at least one flanking amino acid.
120 . A pharmaceutical composition comprising the fusion protein of claim 118 and a pharmaceutically acceptable carrier.
121 . A vaccine comprising:
a) the fusion protein of claim 118 , and b) a pharmaceutically acceptable carrier.
122 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide or fragment of claim 98 .
123 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 118 .
124 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 122 or 123 .
125 . The method of claim 124 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
126 . The method of claim 124 , wherein said DNA vaccine is capable of generating an immune response in said subject.
127 . The method of claim 124 , wherein said bacterial infection is Chlamydia infection.
128 . The method of claim 127 , wherein said subject has or is at risk for contracting Chlamydia.
129 . An isolated CT781 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 5, or fragment thereof, wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
130 . The polypeptide or fragment of claim 129 , wherein said polypeptide or fragment, when administered to a mammal, elicits an immune response.
131 . The polypeptide or fragment of claim 129 , wherein said polypeptide or fragment elicits a CD8 + T-cell response.
132 . The polypeptide or fragment of claim 129 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
133 . The fragment of claim 129 , wherein said fragment is fewer than 500 amino acids in length.
134 . The fragment of claim 133 , wherein said fragment is fewer than 400 amino acids in length.
135 . The fragment of claim 134 , wherein said fragment is fewer than 300 amino acids in length.
136 . The fragment of claim 135 , wherein said fragment is fewer than 200 amino acids in length.
137 . The fragment of claim 136 , wherein said fragment is fewer than 100 amino acids in length.
138 . The fragment of claim 137 , wherein said fragment is fewer than 50 amino acids in length.
139 . The fragment of claim 138 , wherein said fragment is fewer than 30 amino acids in length.
140 . The fragment of claim 139 , wherein said fragment is fewer than 15 amino acids in length.
141 . The polypeptide or fragment of claim 129 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 5.
142 . The polypeptide or fragment of claim 141 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
143 . The polypeptide or fragment of claim 141 , wherein said polypeptide or fragment contains at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 5.
144 . The polypeptide or fragment of claim 143 , wherein said polypeptide or fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 5.
145 . A pharmaceutical composition comprising the polypeptide or fragment of claim 129 in a pharmaceutically acceptable carrier.
146 . A vaccine comprising:
a) the polypeptide or fragment of claim 129 , and b) a pharmaceutically acceptable carrier.
147 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide or fragment of claim 129 .
148 . The method of claim 147 , wherein said polypeptide or fragment is in a pharmaceutically acceptable carrier.
149 . The method of claim 147 , wherein said polypeptide or fragment is capable of generating an immune response in said subject.
150 . The method of claim 147 , wherein said bacterial infection is Chlamydia infection.
151 . The method of claim 150 , wherein said subject has or is at risk for contracting Chlamydia.
152 . An isolated fusion protein comprising:
a) the polypeptide or fragment of claim 129 ; and b) a fusion partner.
153 . The fusion protein of claim 152 , wherein said fragment comprises at least one flanking amino acid.
154 . A pharmaceutical composition comprising the fusion protein of claim 152 and a pharmaceutically acceptable carrier.
155 . A vaccine comprising:
a) the fusion protein of claim 152 , and b) a pharmaceutically acceptable carrier.
156 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide or fragment of claim 129 .
157 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 152 .
158 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 156 or 157 .
159 . The method of claim 158 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
160 . The method of claim 158 , wherein said DNA vaccine is capable of generating an immune response in said subject.
161 . The method of claim 158 , wherein said bacterial infection is Chlamydia infection.
162 . The method of claim 161 , wherein said subject has or is at risk for contracting Chlamydia.
163 . An isolated CT808 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 6, or fragment thereof, wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
164 . The polypeptide or fragment of claim 163 , wherein said polypeptide or fragment, when administered to a mammal, elicits an immune response.
165 . The polypeptide or fragment of claim 163 , wherein said polypeptide or fragment elicits a CD8 + T-cell response.
166 . The polypeptide or fragment of claim 163 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
167 . The fragment of claim 163 , wherein said fragment is fewer than 500 amino acids in length.
168 . The fragment of claim 167 , wherein said fragment is fewer than 400 amino acids in length.
169 . The fragment of claim 168 , wherein said fragment is fewer than 300 amino acids in length.
170 . The fragment of claim 169 , wherein said fragment is fewer than 200 amino acids in length.
171 . The fragment of claim 170 , wherein said fragment is fewer than 100 amino acids in length.
172 . The fragment of claim 171 , wherein said fragment is fewer than 50 amino acids in length.
173 . The fragment of claim 172 , wherein said fragment is fewer than 30 amino acids in length.
174 . The fragment of claim 173 , wherein said fragment is fewer than 15 amino acids in length.
175 . The polypeptide or fragment of claim 163 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 6.
176 . The polypeptide or fragment of claim 175 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
177 . The polypeptide or fragment of claim 175 , wherein said polypeptide or fragment contains at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 6.
178 . The polypeptide or fragment of claim 177 , wherein said polypeptide or fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 6.
179 . A pharmaceutical composition comprising the polypeptide or fragment of claim 163 in a pharmaceutically acceptable carrier.
180 . A vaccine comprising:
a) the polypeptide or fragment of claim 163 , and b) a pharmaceutically acceptable carrier.
181 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide or fragment of claim 163 .
182 . The method of claim 181 , wherein said polypeptide or fragment is in a pharmaceutically acceptable carrier.
183 . The method of claim 181 , wherein said polypeptide or fragment is capable of generating an immune response in said subject.
184 . The method of claim 181 , wherein said bacterial infection is Chlamydia infection.
185 . The method of claim 184 , wherein said subject has or is at risk for contracting Chlamydia.
186 . An isolated fusion protein comprising:
a) the polypeptide or fragment of claim 163 ; and b) a fusion partner.
187 . The fusion protein of claim 186 , wherein said fragment comprises at least one flanking amino acid.
188 . A pharmaceutical composition comprising the fusion protein of claim 186 and a pharmaceutically acceptable carrier.
189 . A vaccine comprising:
a) the fusion protein of claim 186 , and b) a pharmaceutically acceptable carrier.
190 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide or fragment of claim 163 .
191 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 186 .
192 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 190 or 191 .
193 . The method of claim 192 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
194 . The method of claim 192 , wherein said DNA vaccine is capable of generating an immune response in said subject.
195 . The method of claim 192 , wherein said bacterial infection is Chlamydia infection.
196 . The method of claim 195 , wherein said subject has or is at risk for contracting Chlamydia.
197 . An isolated CT823 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 7, or fragment thereof, wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
198 . The polypeptide or fragment of claim 197 , wherein said polypeptide or fragment, when administered to a mammal, elicits an immune response.
199 . The polypeptide or fragment of claim 197 , wherein said polypeptide or fragment elicits a CD8 + T-cell response.
200 . The polypeptide or fragment of claim 197 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
201 . The fragment of claim 197 , wherein said fragment is fewer than 400 amino acids in length.
202 . The fragment of claim 201 , wherein said fragment is fewer than 300 amino acids in length.
203 . The fragment of claim 202 , wherein said fragment is fewer than 200 amino acids in length.
204 . The fragment of claim 203 , wherein said fragment is fewer than 100 amino acids in length.
205 . The fragment of claim 204 , wherein said fragment is fewer than 50 amino acids in length.
206 . The fragment of claim 205 , wherein said fragment is fewer than 30 amino acids in length.
207 . The fragment of claim 206 , wherein said fragment is fewer than 15 amino acids in length.
208 . The polypeptide or fragment of claim 197 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 7.
209 . The polypeptide or fragment of claim 208 , wherein said polypeptide or fragment comprises at least one flanking amino acid.
210 . The polypeptide or fragment of claim 208 , wherein said polypeptide or fragment contains at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 7.
211 . The polypeptide or fragment of claim 210 , wherein said polypeptide or fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 7.
212 . A pharmaceutical composition comprising the polypeptide or fragment of claim 197 in a pharmaceutically acceptable carrier.
213 . A vaccine comprising:
a) the polypeptide or fragment of claim 197 , and b) a pharmaceutically acceptable carrier.
214 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide or fragment of claim 197 .
215 . The method of claim 214 , wherein said polypeptide or fragment is in a pharmaceutically acceptable carrier.
216 . The method of claim 214 , wherein said polypeptide or fragment is capable of generating an immune response in said subject.
217 . The method of claim 214 , wherein said bacterial infection is Chlamydia infection.
218 . The method of claim 217 , wherein said subject has or is at risk for contracting Chlamydia.
219 . An isolated fusion protein comprising:
a) the polypeptide or fragment of claim 197 ; and b) a fusion partner.
220 . The fusion protein of claim 219 , wherein said fragment comprises at least one flanking amino acid.
221 . A pharmaceutical composition comprising the fusion protein of claim 219 and a pharmaceutically acceptable carrier.
222 . A vaccine comprising:
a) the fusion protein of claim 219 , and b) a pharmaceutically acceptable carrier.
223 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide or fragment of claim 197 .
224 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 219 .
225 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 223 or 224 .
226 . The method of claim 225 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
227 . The method of claim 225 , wherein said DNA vaccine is capable of generating an immune response in said subject.
228 . The method of claim 225 , wherein said bacterial infection is Chlamydia infection.
229 . The method of claim 228 , wherein said subject has or is at risk for contracting Chlamydia.
230 . An isolated CT062 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 8, wherein said polypeptide elicits at least an 40-fold increase interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
231 . The polypeptide of claim 230 , wherein said polypeptide, when administered to a mammal, elicits an immune response.
232 . The polypeptide of claim 230 , wherein said polypeptide elicits a CD8 + T-cell response.
233 . The polypeptide claim 230 , wherein said polypeptide comprises at least one flanking amino acid.
234 . The polypeptide of claim 230 , wherein said polypeptide contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 8.
235 . The polypeptide of claim 234 , wherein said polypeptide comprises at least one flanking amino acid.
236 . The polypeptide claim 234 , wherein said polypeptide contains at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 8.
237 . The polypeptide of claim 236 , wherein said polypeptide contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 8.
238 . A pharmaceutical composition comprising the polypeptide of claim 230 in a pharmaceutically acceptable carrier.
239 . A vaccine comprising:
a) the polypeptide of claim 230 , and b) a pharmaceutically acceptable carrier.
240 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the polypeptide of claim 230 .
241 . The method of claim 240 , wherein said polypeptide is in a pharmaceutically acceptable carrier.
242 . The method of claim 240 , wherein said polypeptide is capable of generating an immune response in said subject.
243 . The method of claim 240 , wherein said bacterial infection is Chlamydia infection.
244 . The method of claim 243 , wherein said subject has or is at risk for contracting Chlamydia.
245 . An isolated fusion protein comprising:
a) the polypeptide of claim 230 ; and b) a fusion partner.
246 . The fusion protein of claim 245 , wherein said polypeptide comprises at least one flanking amino acid.
247 . A pharmaceutical composition comprising the fusion protein of claim 245 and a pharmaceutically acceptable carrier.
248 . A vaccine comprising:
a) the fusion protein of claim 245 , and b) a pharmaceutically acceptable carrier.
249 . A DNA vaccine comprising a polynucleotide sequence that encodes the polypeptide of claim 230 .
250 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 245 .
251 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 249 or 250 .
252 . The method of claim 251 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
253 . The method of claim 251 , wherein said DNA vaccine is capable of generating an immune response in said subject.
254 . The method of claim 251 , wherein said bacterial infection is Chlamydia infection.
255 . The method of claim 254 , wherein said subject has or is at risk for contracting Chlamydia.
256 . An isolated CT062 fragment comprising an amino acid sequence substantially identical to SEQ ID NO: 9, wherein said fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.
257 . The fragment of claim 256 , wherein said fragment, when administered to a mammal, elicits an immune response.
258 . The fragment of claim 256 , wherein said fragment elicits a CD8 + T-cell response.
259 . The fragment of claim 256 , wherein said fragment comprises at least one flanking amino acid.
260 . The fragment of claim 256 , wherein said fragment is fewer than 300 amino acids in length.
261 . The fragment of claim 260 , wherein said fragment is fewer than 200 amino acids in length.
262 . The fragment of claim 261 , wherein said fragment is fewer than 100 amino acids in length.
263 . The fragment of claim 262 , wherein said fragment is fewer than 50 amino acids in length.
264 . The fragment of claim 263 , wherein said fragment is fewer than 30 amino acids in length.
265 . The fragment of claim 264 , wherein said fragment is fewer than 15 amino acids in length.
266 . The fragment of claim 256 , wherein said fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 9.
267 . The fragment of claim 266 , wherein said fragment comprises at least one flanking amino acid.
268 . The fragment of claim 266 , wherein said fragment contains at least three conservative amino acid substitutions in the sequence of SEQ ID NO: 9.
269 . The fragment of claim 268 , wherein said fragment contains at least five conservative amino acid substitutions in the sequence of SEQ ID NO: 9.
270 . A pharmaceutical composition comprising the fragment of claim 256 in a pharmaceutically acceptable carrier.
271 . A vaccine comprising:
a) the fragment of claim 256 , and b) a pharmaceutically acceptable carrier.
272 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the fragment of claim 256 .
273 . The method of claim 272 , wherein said fragment is in a pharmaceutically acceptable carrier.
274 . The method of claim 272 , wherein said fragment is capable of generating an immune response in said subject.
275 . The method of claim 272 , wherein said bacterial infection is Chlamydia infection.
276 . The method of claim 275 , wherein said subject has or is at risk for contracting Chlamydia.
277 . An isolated fusion protein comprising:
a) the fragment of claim 256 ; and b) a fusion partner.
278 . The fusion protein of claim 277 , wherein said fragment comprises at least one flanking amino acid.
279 . A pharmaceutical composition comprising the fusion protein of claim 277 and a pharmaceutically acceptable carrier.
280 . A vaccine comprising:
a) the fusion protein of claim 277 , and b) a pharmaceutically acceptable carrier.
281 . A DNA vaccine comprising a polynucleotide sequence that encodes the fragment of claim 256 .
282 . A DNA vaccine comprising a polynucleotide sequence that encodes the fusion protein of claim 277 .
283 . A method of treating or preventing a bacterial infection, said method comprising administering to a subject in need thereof, a therapeutically effective amount of the DNA vaccine of claim 281 or 282 .
284 . The method of claim 283 , wherein said DNA vaccine is in a pharmaceutically acceptable carrier.
285 . The method of claim 283 , wherein said DNA vaccine is capable of generating an immune response in said subject.
286 . The method of claim 283 , wherein said bacterial infection is Chlamydia infection.
287 . The method of claim 286 , wherein said subject has or is at risk for contracting Chlamydia.Join the waitlist — get patent alerts
Track US2014120129A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.